1. Home
  2. ESYN vs CTXR Comparison

ESYN vs CTXR Comparison

Compare ESYN & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ESYN

EnerSyn Global Inc. Common Stock

N/A

Current Price

$2.64

Market Cap

19.8M

Sector

Health Care

ML Signal

N/A

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.55

Market Cap

18.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESYN
CTXR
Founded
N/A
2007
Country
United States
United States
Employees
4
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.8M
18.7M
IPO Year
2022
2010

Fundamental Metrics

Financial Performance
Metric
ESYN
CTXR
Price
$2.64
$0.55
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $6.00
AVG Volume (30 Days)
25.8K
★ 192.4K
Earning Date
N/A
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 43.38
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$147.57
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.43
$0.47
52 Week High
$2.68
$2.19

Technical Indicators

Market Signals
Indicator
ESYN
CTXR
Relative Strength Index (RSI) N/A 44.72
Support Level N/A $0.55
Resistance Level N/A $0.61
Average True Range (ATR) 0.00 0.03
MACD 0.00 -0.00
Stochastic Oscillator 0.00 35.87

Price Performance

Historical Comparison
ESYN
CTXR

About ESYN EnerSyn Global Inc. Common Stock

EnerSyn Global Inc, formerly HWH International Inc and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore. The Company is presently developing Hapi Marketplace, a business-to-consumer platform featuring diverse product categories, and Hapi Wealth Builder, an educational program focused on wealth-building strategies.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: